Compare Mutual Funds
Select a Mutual Fund
Risk | Very High | - |
Rating | - | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 2.34 | - |
NAV | ₹12.74 | - |
Fund Started | 20 Nov 2023 | - |
Fund Size | ₹467.92 Cr | - |
Exit Load | 0.5% for redemption within 30 Days | - |
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹100
-
Expense Ratio
2.34
-
NAV
₹12.74
-
Fund Started
20 Nov 2023
-
Fund Size
₹467.92 Cr
-
Exit Load
0.5% for redemption within 30 Days
-
1 Year | -4.68% | - |
3 Year | - | - |
5 Year | - | - |
1 Year
-4.68%
-
3 Year
-
-
5 Year
-
-
Equity | 96.25% | - |
Cash | 3.75% | - |
Equity
96.25%
-
Cash
3.75%
-
Top 10 Holdings |
| - |
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 12.86% |
Max Healthcare Institute Ltd. | 7.26% |
JB Chemicals & Pharmaceuticals Ltd. | 6.26% |
Divi's Laboratories Ltd. | 5.46% |
Cipla Ltd. | 4.84% |
Lupin Ltd. | 4.28% |
Apollo Hospitals Enterprise Ltd. | 3.99% |
Fortis Healthcare Ltd. | 3.78% |
Acutaas Chemicals Ltd. | 3.28% |
Jubilant Pharmova Ltd. | 3.21% |
-
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors. | - |
Launch Date | 20 Nov 2023 | - |
Description
The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors.
-
Launch Date
20 Nov 2023
-